What Orpyx does

Orpyx Medical Technologies Inc. is a Calgary-based health technology company founded in 2010 by CEO Dr. Breanne Everett, specializing in remote monitoring solutions that prevent diabetic foot ulcers (DFUs) and amputations. Its core product is the Orpyx SI Sensory Insole program: custom-fitted insoles with embedded toe-to-heel pressure, temperature, motion, and adherence sensors that transmit data via a cellular "Hub" to a cloud platform, paired with a mobile app that delivers real-time audiovisual alerts when dangerous pressure or inflammation events are detected. US-based registered nurses provide between-visit coaching, adherence support, and escalation under a remote patient monitoring service.

The company sells its hardware and services primarily through healthcare providers (podiatrists, endocrinologists, wound-care specialists), health systems, and payers across North America, with a specialized distribution channel — Marathon Medical Corporation, an SDVOSB — covering Veterans Affairs Medical Centers under the VA National Initiative to End Diabetic Limb Loss. Revenue is generated through one-time hardware sales (Orpyx SI and SI Flex insoles, HCPCS A5514) and recurring remote physiological monitoring services billed under CPT codes 99453, 99454, 99457, and 99458. Clinical evidence is central to the model: a randomized controlled trial published in The Lancet Digital Health (2019) demonstrated an 86% reduction in DFU recurrence when the system was worn 4.5+ hours per day, and Orpyx is currently supplying its digital health platform to the NIH-funded WIREDUP trial led by Johns Hopkins. The company employs 11–50 people, is privately held, and is backed by Perceptive Advisors following a $20M round in September 2024.

Name

Orpyx

Legal name

Orpyx Medical Technologies Inc.

Website

https://orpyx.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Orpyx Medical Technologies develops sensor-enabled smart insoles and remote patient monitoring services that detect early signs of diabetic foot ulcers, serving diabetic patients, podiatrists, payers, and the Veterans Health Administration across North America.

Ownership category

akta.pro rank

Product category

Diabetic Foot Care Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Orthopedics & Sports Medicine Telemedicine Platforms (HLALAGAO)

akta.pro secondary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Diabetic foot care
• Remote patient monitoring
• Sensor insoles
• Medical wearables
• DFU prevention

Headquarters

HQ city

Calgary

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Sensory Insole Hardware Sales: Sale of Orpyx SI Sensory Insoles, the core hardware product. The insoles function for 4-6 months without charging and are custom-fitted for patients. Revenue is generated through initial device sales to patients via healthcare providers.
2. Remote Patient Monitoring Services: RPM services bundled with the device program, including US-based nurse monitoring, data analytics, coaching, and escalation services. Billed using CPT codes 99453, 99454, 99457, 99458 for remote physiological monitoring.
3. Digital Health Platform Licensing: Orpyx provides its full digital health platform for clinical trials and research partnerships, generating revenue through NIH-funded trials and academic collaborations.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Orpyx develops and sells the Orpyx SI Sensory Insole Program, a patented sensor-enabled smart insole system for people with diabetes at risk of diabetic foot ulcers. The product pairs custom insoles with embedded multimodal sensors (plantar pressure, temperature, activity, adherence) and a cellular-connected Hub that uploads data to a cloud platform monitored by a US-based remote nursing team. It is sold to healthcare providers, health systems, payers, and the Veterans Health Administration, with the company also licensing its digital health platform for NIH-funded clinical trials.

Product overview

Orpyx is a med tech + touch company offering a unified product ecosystem centered on the Orpyx SI Sensory Insole system. The core offering comprises sensory insoles with embedded sensors, the Orpyx Hub (cellular data bridge), the Orpyx mobile App, and the Orpyx Dashboard for healthcare providers. These components work together to continuously monitor plantar pressure, temperature, activity, and adherence data, automatically uploading to the cloud for remote patient monitoring. The Between Visit Services module provides US-based nursing support for coaching and early intervention. The company also offers specialized solutions for Veterans Affairs (RPPM) and supplies its digital health platform for NIH-funded clinical trials. Product variants include the Orpyx SI Flex Sensory Insoles.

Differentiator

Problem solved

Functional benefit

Brands

• Orpyx SI Sensory Insoles: Sensor-enabled smart insole system that continuously monitors plantar pressure, temperature, step count, and wear time to help prevent diabetic foot ulcers.
• Orpyx SI Flex

Products and services

• Orpyx SI Sensory Insole Program Sensor-enabled smart insole program for people with diabetes at risk of diabetic foot ulcers; combines custom insoles with multimodal pressure/temperature/activity/adherence sensors, a cellular-connected Hub, mobile app, and provider Dashboard, with US-based remote nursing support. Sold to healthcare providers, health systems, payers, and the VA.
• Orpyx SI Flex Sensory Insoles Flexible variant of the Orpyx SI sensory insole offering enhanced comfort and fit while maintaining continuous plantar pressure, temperature, activity, and adherence monitoring for diabetic foot ulcer prevention.
• Orpyx Between Visit Services (RPM Nursing Program) Recurring remote patient monitoring service featuring a US-based dedicated nursing team that reviews sensory insole data, provides coaching and adherence support, conducts wellness checks, and escalates concerns to providers when needed; bundled with the Sensory Insole Program and billable under US RPM CPT codes.
• VA Remote Patient Pedal Monitoring (RPPM) Solution Veterans Affairs-tailored remote patient monitoring solution combining the Orpyx sensory insole hardware, Hub, and remote nursing program for Veterans at risk of diabetic foot ulcers, deployed through VA Medical Centers and the Marathon Medical Corporation SDVOSB authorized distributor.
• Digital Health Platform for Clinical Trials Licensed research offering in which Orpyx supplies its sensory insoles, cloud analytics platform, and remote monitoring program to academic and NIH-funded clinical trials investigating digital foot monitoring for diabetic foot ulcer prevention.

Quantifiable outcome

• 86% reduction in diabetic foot ulcer recurrence when Orpyx technology worn 4.5+ hours/day
• +5 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered core, major, minor and advisory.

• Marathon Medical CorporationcoreChannel Partner/ Reseller/ DistributorAuthorized distributor of Orpyx Sensory Insoles for the VA market. Marathon Medical is a Service-Disabled Veteran-Owned Small Business (SDVOSB) headquartered in Aurora, Colorado, specializing in delivering premium medical supplies nationwide.
• Johns Hopkins University School of MedicinemajorStrategic or Co-development PartnerJohns Hopkins leads the $5 million NIH-funded WIREDUP clinical trial (R01) using Orpyx technology. The study will enroll 400 participants to test whether continuous digital foot monitoring can reduce diabetic foot ulcer incidence.
• Keck Medicine of USCmajorStrategic or Co-development PartnerCollaborator in the NIH-funded WIREDUP clinical trial, bringing expertise in diabetic foot care research.
• University of Utah Spencer Fox Eccles School of MedicinemajorStrategic or Co-development PartnerCollaborator in the NIH-funded WIREDUP clinical trial.
• Siksika Health ServicesminorStrategic or Co-development PartnerIndigenous health organization collaborating with Orpyx through the PATHWAYS Indigenous Health Collaborations Program to enhance foot health and prevent diabetic foot ulcers among Siksika Nation members.
• GMAK ConsultingminorStrategic or Co-development PartnerConsulting partner in the PATHWAYS Indigenous Health Collaborations Program with Siksika Health Services and Orpyx.
• Dr. David Shulkin (Former VA Secretary)advisoryOthersFormer U.S. Secretary of Veterans Affairs joined Orpyx Advisory Board in October 2025 to advance Veteran care and diabetes prevention market growth. Brings expertise in VA policy and healthcare innovation adoption.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Market position

Weaknesses5 records

Competitive moat5 records

Customer concentration

• Xx.com/orpyxinc
• Facebookfacebook.com/orpyxinc
• LinkedInlinkedin.com/company/orpyx-medical-technologies

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds8 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orpyx